The Medicines Company Aims For Mid-2008 Cleviprex Launch
This article was originally published in The Pink Sheet Daily
Executive Summary
The third-generation, acute care calcium channel blocker’s FDA user fee date is in May 2008, COO Kelley tells “The Pink Sheet” DAILY.
You may also be interested in...
Can The Medicines Company Rebound From A Phase III Blow?
Antithrombotic cangrelor fails against Plavix in angioplasty, but the company says the drug’s profile lends to an indication as a bridge therapy for surgery patients who can’t stay on clopidogrel.
Can The Medicines Company Rebound From A Phase III Blow?
Antithrombotic cangrelor fails against Plavix in angioplasty, but the company says the drug’s profile lends to an indication as a bridge therapy for surgery patients who can’t stay on clopidogrel.
Can The Medicines Company Rebound From A Phase III Blow?
The Medicines Company will focus development of its reversible antithrombotic cangrelor on use as a "bridging" drug for patients who must break from Sanofi Aventis/Bristol-Myers Squibb's Plavix (clopidogrel) while undergoing surgery, after halting two Phase III trials in angioplasty patients because it was not showing approvable efficacy